The L-Histidine Market Size was valued at USD 0.71 billion in 2023. The L-Histidine market industry is projected to grow from USD 0.79 Billion in 2024 to USD 1.65 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.6% during the forecast period (2024 - 2032). The Advancements in technology for the diagnosis and treatment of chronic illnesses and autoimmune disorders are becoming more common and are the key market drivers enhancing market growth.
The incidence of autoimmune disorders and chronic diseases like cancer, diabetes, and rare disorders is rising, as well as technological advancements in treating and diagnosing these conditions. The rising demand provides a further opportunity for market expansion for affordable therapeutics in developing nations and a rise in the number of new drugs approved for treating chronic illnesses. However, the lengthy manufacturing process and strict rules and regulations regarding the facilities and equipment needed for L-histidine drugs may damage the L-histidine drug market.
Histidine was first discovered in 1896 by the German physician Albrecht Kossel. Histidine was initially believed to be an amino acid that was only necessary for infants, but a 1975 study proved it is also necessary for adults. L-histidine is a small molecule that humans can biosynthesize, but this level is insufficient to meet nutritional needs. The best dietary sources of L-histidine are items that contain animal protein, like meat and dairy products. L-histidine amounts are also in cereal grains like wheat, rye, and rice. L-histidine (HIS), an essential amino acid, also plays specific roles in erythropoiesis, the L-Histidinergic system, reactive oxygen and nitrogen species scavenging, metal ion chelation, proton buffering, and erythropoiesis. Several HIS-rich proteins (e.g., HIS-containing glycoproteins, statins, HIS-rich calcium-binding protein, and filaggrin), HIS-containing dipeptides (particularly carnosine), and methyl- and sulfur-containing derivatives of HIS (3-methylhistidine, 1-methylhistidine, and ergothioneine) all have particular roles. The theoretical justification for recommending HIS supplementation in various conditions is based on its distinct chemical properties and physiological functions. Experience spanning several decades has validated the efficacy of HIS as a component of treatments for organ preservation and myocardial protection in cardiac surgery. Additional research is required to clarify the effects of HIS supplementation on neurological conditions, atopic dermatitis, metabolic syndrome, diabetes, uraemic anemia, ulcers, inflammatory bowel diseases, malignancies, and muscle performance during strenuous exercise has enhanced the L-Histidine market CAGR across the globe in recent years.
Additionally, L-Histidine is created by the amino acid's decarboxylation, and L-histidine hydrochloride is its essential precursor. In laboratory animals, tissue L-Histidine levels rise as dietary L-histidine intake rises. This is most likely the situation in people as well. The immunomodulatory and antioxidant properties of L-Histidine are well-known. L-Histidine causes the H2 receptors on suppressor T cells to become active. It may be advantageous for rheumatoid arthritis to encourage suppressor T cell activity.
However, the main source of the biochemical activity of L-histidine comes from its imidazole side chain. This region serves as the catalytic site for some enzymes and is also involved in producing metalloproteins. L-histidine plays a role in stabilizing oxygen-bound hemoglobin and destabilizing carbon monoxide-bound hemoglobin, which contributes to its significance in blood chemistry. L-histidine is frequently sold as L-histidine HCl, the hydrochloride salt of L-histidine. The usual method for making this salt involves neutralizing L-histidine with hydrochloric acid, another factor driving the growth of the L-Histidine market revenue.
Based on Product type, the L-Histidine market segmentation includes tablets, capsules, fluids and others. The Tablet segment held the majority share in 2022, contribution to the L-Histidine market revenue. A tablet is a capsule that contains only medicine. A solid, smooth pill is created by compressing a powdered medication. For tablet medications, various shapes and colors, such as round or oblong (caplets), are possible. For easier splitting, some tablets have lines on them. Compared to capsules, tablets are usually more stable and durable. Their chewability facilitates the ingestion of some tablets. More medication can be squeezed into a tablet by the manufacturer. You can cut a tablet in half or thirds to maximize your dose. Delayed-release (DR), extended-release (ER), and immediate-release (IR) formulations of tablet medications are all readily available.
Figure 1 L-Histidine Market, by Type, 2022 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on application, the L-Histidine market segmentation includes the food, pharmaceutical, biotechnology, and medical industries. The food industry segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The U.S. Food and Nutrition Board (FNB) is a government agency. RDAs (Recommended Dietary Allowances) for essential amino acids were established by the Institute of Medicine in 2002. Adults aged 19 and over should take histidine at a daily dose of 14 mg/kg body weight. Numerous conditions, such as neurological disorders, atopic dermatitis, metabolic syndrome, diabetes, uraemic anemia, ulcers, inflammatory bowel diseases, malignancies, and muscle performance during strenuous exercise, are being studied concerning the use of supplemental histidine is positively impacting the L-Histidine market growth.
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America L-Histidine market accounted for USD 0.274 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is because of the high cost of healthcare and favorable treatment reimbursement policies. In the United States, health insurance is infamously costly and confusing. In contrast to Canada, most of Europe, and many other nations, where universal health care guarantees all citizens a minimal level of protection, the U.S. offers two types of government-run programs and a mix of private ones. While comparable plans in New York can cost upwards of $600 per month, basic coverage in California and Florida can cost as little as $450 per month.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 L-HISTIDINE MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s L-Histidine market accounts for the second-largest market share due to increased genetic disorders and the presence of refined medical facilities. Over 7000 rare diseases have been registered to date, and 80% of them are genetic. Further, the German L-Histidine market held the largest market share, and the UK L-Histidine market was the fastest-growing market in the European region.
The Asia-Pacific L-Histidine Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because there is a growing need for affordable therapeutics, and cancer incidence is steadily rising. After cardiovascular disease, cancer is the second leading cause of death in the Asia-Pacific region. An estimated 4.5 million deaths (or 16.3 percent of all deaths) were attributed to cancer in the Asia-Pacific region in 2022. Moreover, China’s L-Histidine market held the largest market share, and the Indian L-Histidine market was the fastest-growing market in the Asia-Pacific region.
L-Histidine Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the L-Histidine market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the L-Histidine industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies manufacturers adopt in the L-Histidine industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. The L-Histidine industry has provided medicine with some of the most significant benefits in recent years. The L-Histidine market major player such as Angene Chemicals (UK), Douglas Laboratories(US), Zealing Chemical Co. Ltd (Thailand), MolPort, ABI Chemical, Acron Pharma Tech, Shine Star Biological Engineering, Changzhou Highassay Chemical Co. Ltd, Ajinomoto (Japan), Kyowa Hakko Bio, Huaheng Biological, Twinlabs(US), MyProtein(UK) and others are working on expanding the market demand by investing in research and development activities.
Angene Chemicals (UK), Angene is committed to offering top-notch chemicals for use in both industrial manufacturing and research and development. Angenes provides more than 100,000 products, including laboratory reagents, intermediates, bulk goods, agro-chemicals, natural ingredients, and active pharmaceutical ingredients (APIs). In addition to its 100,000 products, Angene offers custom synthesis of chemicals that are not readily available in the market.
Also, Douglas Laboratories (US) For more than 60 years, Douglas Laboratories® has devoted itself to serving healthcare professionals’ needs and is a pioneer in creating premium, innovative nutritional supplements based on science and supporting 12 different health functions. Learn how Douglas Laboratories can encourage your patients to live healthier lives now and in the future.
Key Companies in the L-Histidine market include
L-Histidine Industry Developments
January 2022 An essential amino acid used in the biosynthesis of proteins is histidine, abbreviated as His or H. It is classified as a positively charged amino acid at physiological pH because it has an -amino group, which is in the protonated -NH3 form under biological conditions, a carboxylic acid group, which is in the deprotonated -COO form under biological conditions, and an imidazole side chain, which is partially protonated. It was once believed to be necessary only for infants, but more recent studies have shown that adults also require it. Codons CAU and CAC serve as its encoding. Albrecht Kossel and Sven Gustaf Hedin isolated histidine for the first time in 1896. Additionally, it functions as a precursor to L-Histidine, a key inflammatory compound in immune responses. Histidyl serves as the acyl radical.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.71 billion |
| Market Size 2024 | USD 0.79 billion |
| Market Size 2032 | USD 1.65 billion |
| Compound Annual Growth Rate (CAGR) | 8.6% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Angene Chemicals (UK), Douglas Laboratories (US), Zealing Chemical Co. Ltd (Thailand), MolPort, ABI Chemical, Acron Pharma Tech, Shine Star Biological Engineering, Changzhou Highassay Chemical Co. Ltd, Ajinomoto (Japan), Kyowa Hakko Bio, Huaheng Biological, Twinlabs (US), MyProtein(UK) and others. |
| Key Market Opportunities | Distinct chemical properties and physiological functions |
| Key Market Dynamics | Incidence of autoimmune disorders and chronic diseases |
L-Histidine Market Highlights:
Frequently Asked Questions (FAQ) :
The L-Histidine market size was valued at USD 0.71 Billion in 2023.
The market is projected to grow at a CAGR of 8.6% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Angene Chemicals (UK), Douglas Laboratories (US), Zealing Chemical Co. Ltd (Thailand), MolPort, ABI Chemical, Acron Pharma Tech, Shine Star Biological Engineering, Changzhou Highassay Chemical Co. Ltd, Ajinomoto (Japan), Kyowa Hakko Bio, Huaheng Biological, Twinlabs(US), MyProtein(UK) and others.
The Tablet Product type segment dominated the market in 2023.
The Food Industry had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
